Bull Sessions (10/17/2023)

*"Oh. It's on ... it's definitely on."* We'll kick off the Bull Session Cage Challenge as investors are invited to bring out your strongest high-conviction buying opportunities coupled with a selling suggestion as the "source of funds." Selling stocks is not easy and the lessons will likely flow ...

In this October 17, 2023 Bull Sessions episode, Mark Robertson hosts Matt Spielman, Ty Hughes, Kim Butcher, and Kevin Gillogly for a discussion on market dynamics and small-cap stock opportunities. The panel examines the current market bifurcation where the largest companies, particularly the "Magnificent Seven," are dominating performance while smaller companies present more attractive valuations. The hosts review the Manifest Investing median projected annual return (MIPAR) forecasts and note that after a hot August, more stocks have come "on sale" in recent weeks, creating opportunities for value-oriented investors. The discussion touches on the momentum effect of index fund investing and its potential impact on market structure.

The panel engages in substantive analysis of several hot stocks, including pharmaceutical and biotech companies benefiting from GLP-1 weight-loss drug development. Matt Spielman highlights Eli Lilly's remarkable 100% gain since March and discusses Novo Nordisk's role in the sector alongside Vertex Pharmaceuticals and CRISPR Therapeutics, which awaits an FDA decision in early December. Progressive Insurance is examined as an unexpected beneficiary, potentially due to a quiet hurricane season. The session emphasizes the importance of thorough fundamental analysis and the philosophy of finding quality companies at reasonable prices rather than chasing momentum in mega-cap stocks.